Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Wirksamkeits- und Sicherheitsstudie zu Nipocalimab bei Erwachsenen mit chronisch entzündlicher demyelinisierender Polyneuropathie (CIDP)

2. November 2026 aktualisiert von: Janssen Research & Development, LLC

Phase 2/3, mehrstufige, multizentrische, randomisierte, doppelblinde, Placebo-kontrollierte Parallelgruppen-Entzugsstudie zur Bewertung der Wirksamkeit und Sicherheit von Nipocalimab bei der Verabreichung an Erwachsene mit chronisch entzündlicher demyelinisierender Polyneuropathie (CIDP)

The main purpose of this study is to evaluate the safety and efficacy of nipocalimab compared to placebo in delaying relapse in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) who initially respond to nipocalimab in Stage A.

Studienübersicht

Status

Rekrutierung

Bedingungen

Intervention / Behandlung

Studientyp

Interventionell

Einschreibung (Geschätzt)

201

Phase

  • Phase 2
  • Phase 3

Erweiterter Zugriff

Vorübergehend nicht verfügbar außerhalb der klinischen Studie. Siehe erweiterter Zugriffsdatensatz.

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

      • Buenos Aires, Argentinien, C1199ABB
        • Aktiv, nicht rekrutierend
        • Hospital Italiano de Buenos Aires
      • Buenos Aires, Argentinien, C1428AQK
        • Rekrutierung
        • Instituto Fleni
      • Buenos Aires, Argentinien, C1428
        • Abgeschlossen
        • Hospital Gral Agudos Ignacio Pirovano
      • Rosario, Argentinien, 2900
        • Rekrutierung
        • INECO Neurociencias Orono
      • Melbourne, Australien, 3004
        • Abgeschlossen
        • The Alfred Hospital
      • Parkwood, Australien, 4215
        • Abgeschlossen
        • Gold Coast University Hospital
      • Beijing, China, 100191
        • Abgeschlossen
        • Peking University Third Hospital
      • Beijing, China, 100034
        • Abgeschlossen
        • Peking University First Hospital
      • Beijing, China, 100053
        • Aktiv, nicht rekrutierend
        • Xuanwu Hospital ,Capital Medical University
      • Beijing, China, 100070
        • Aktiv, nicht rekrutierend
        • Beijing Tiantan Hospital, Capital Medical University
      • Changchun, China, 130021
        • Aktiv, nicht rekrutierend
        • The First Hospital of Jilin University
      • Changsha, China, 410008
        • Abgeschlossen
        • Xiangya Hospital Central South University
      • Changsha, China, 410008
        • Aktiv, nicht rekrutierend
        • The Third Xiangya Hospital of Central Sourth University
      • Chengdu, China, 610072
        • Abgeschlossen
        • Sichuan Provincial Peoples Hospital
      • Chifeng, China, 024000
        • Abgeschlossen
        • Chifeng Municipal Hospital
      • Fuzhou, China, 350001
        • Aktiv, nicht rekrutierend
        • Fujian Medical University Union Hospital
      • Guangzhou, China, 510080
        • Aktiv, nicht rekrutierend
        • The First Affiliated Hospital Sun Yat sen University
      • Jinan, China, 250012
        • Aktiv, nicht rekrutierend
        • Qilu Hospital of Shandong University
      • Jinan, China, 250014
        • Abgeschlossen
        • Qianfoshan hospital of Shandong Province
      • Nanchang, China, 330006
        • Aktiv, nicht rekrutierend
        • The First Affiliated Hospital of NanChang University
      • Shanghai, China, 200336
        • Abgeschlossen
        • Tong Ren Hospital Shanghai Jiao Tong University school of medicine
      • Shanghai, China, 200040
        • Aktiv, nicht rekrutierend
        • Huashan Hospital Fudan University
      • Wuhan, China, 430023
        • Abgeschlossen
        • Renmin Hospital of Wuhan University
      • Xi'an, China, 710032
        • Abgeschlossen
        • Tangdu hospital the Fourth Military Medical
      • Xi'an, China, 710075
        • Aktiv, nicht rekrutierend
        • Xi 'an GaoXin Hospital
      • Berlin, Deutschland, 13347
        • Aktiv, nicht rekrutierend
        • Judisches Krankenhaus Berlin
      • Bochum, Deutschland, 44791
        • Abgeschlossen
        • St. Josef-Hospital, Ruhr-Universität Bochum
      • Halle, Deutschland, 6120
        • Aktiv, nicht rekrutierend
        • Städtisches Krankenhaus Martha-Maria Halle-Dölau gGmbH
      • Hanover, Deutschland, 30625
        • Aktiv, nicht rekrutierend
        • Medizinische Hochschule Hannover
      • Leipzig, Deutschland, 4103
        • Abgeschlossen
        • Universitaetsklinikum Leipzig
      • Potsdam, Deutschland, 14471
        • Abgeschlossen
        • St Josefs Krankenhaus Potsdam Sanssouci
      • Bordeaux, Frankreich, 33000
        • Abgeschlossen
        • CHU Bordeaux
      • Bron, Frankreich, 69699
        • Abgeschlossen
        • Hospices Civils de Lyon HCL
      • Le Kremlin-Bicêtre, Frankreich, 94270
        • Aktiv, nicht rekrutierend
        • Hopital de Bicetre
      • Marseille, Frankreich, 13385
        • Aktiv, nicht rekrutierend
        • Hopital de la Timone
      • Nice, Frankreich, 06000
        • Aktiv, nicht rekrutierend
        • Hopital PASTEUR
      • Nîmes, Frankreich, 30029
        • Aktiv, nicht rekrutierend
        • CHU Nimes Hopital Caremeau
      • Paris, Frankreich, 75013
        • Abgeschlossen
        • Hopital de la Pitie Salpetriere
      • Paris, Frankreich, 75019
        • Abgeschlossen
        • Fondation Adolphe de Rothschild Hospital
      • Strasbourg, Frankreich, 67200
        • Aktiv, nicht rekrutierend
        • CHRU Strasbourg
      • Athens, Griechenland, 12462
        • Rekrutierung
        • Attikon General Hospital of Athens
      • Athens, Griechenland, 11527
        • Abgeschlossen
        • Papageorgiou General Hospital Of Thessaloniki
      • Pátrai, Griechenland, 26504
        • Abgeschlossen
        • Patras University Hospital
      • Thessaloniki, Griechenland, 54636
        • Rekrutierung
        • Ahepa Hospital Aristotle University of Thessaloniki
      • Catania, Italien, 95123
        • Abgeschlossen
        • Azienda Ospedaliero-Universitaria Policlinico di Catania
      • Genova, Italien, 16132
        • Abgeschlossen
        • Azienda Ospedaliera Universitaria San Martino di Genova
      • Milan, Italien, 20144
        • Abgeschlossen
        • Casa di Cura del Policlinico
      • Milan, Italien, 20133
        • Abgeschlossen
        • Istituto Neurologico Carlo Besta
      • Naples, Italien, 80131
        • Aktiv, nicht rekrutierend
        • Azienda Ospedaliera di Rilievo Nazionale A Cardarelli
      • Orbassano, Italien, 10043
        • Abgeschlossen
        • Aou San Luigi Gonzaga
      • Pavia, Italien, 27100
        • Abgeschlossen
        • Fondazione Istituto Neurologico Casimiro Mondino
      • Roma, Italien, 00168
        • Abgeschlossen
        • Fondazione Policlinico Universitario A Gemelli IRCCS
      • Rozzano, Italien, 20086
        • Abgeschlossen
        • IRCCS Istituto Clinico Humanitas
      • Asahikawa, Japan, 070-0901
        • Aktiv, nicht rekrutierend
        • National Hospital Organization Asahikawa Medical Center
      • Bunkyō City, Japan, 113 8519
        • Aktiv, nicht rekrutierend
        • Institute of Science Tokyo Hospital
      • Chiba, Japan, 260-8677
        • Abgeschlossen
        • Chiba University Hospital
      • Hamamatsu, Japan, 430-8558
        • Aktiv, nicht rekrutierend
        • Seirei Hamamatsu General Hospital
      • Isehara, Japan, 259-1193
        • Aktiv, nicht rekrutierend
        • Tokai University Hospital
      • Kobe, Japan, 650 0047
        • Abgeschlossen
        • Kobe City Medical Center General Hospital
      • Kodaira-shi, Japan, 187-8551
        • Aktiv, nicht rekrutierend
        • National Center of Neurology and Psychiatry
      • Koshigaya, Japan, 343-8555
        • Aktiv, nicht rekrutierend
        • Saitama Medical Center
      • Kumamoto, Japan, 860-8556
        • Abgeschlossen
        • Kumamoto University Hospital
      • Nagoya, Japan, 466-8560
        • Aktiv, nicht rekrutierend
        • Nagoya University Hospital
      • Nagoya, Japan, 455-8530
        • Aktiv, nicht rekrutierend
        • Chubu Rosai Hospital
      • Osaka Sayama Shi, Japan, 589 8511
        • Abgeschlossen
        • Kindai University Hospital
      • Sendai, Japan, 983-8520
        • Aktiv, nicht rekrutierend
        • National Hospital Organization Sendai Medical Center
      • Shimotsuga Gun, Japan, 321 0293
        • Abgeschlossen
        • Dokkyo Medical University Hospital
      • Shinjuku-ku, Japan, 162-8666
        • Abgeschlossen
        • Tokyo Women's Medical University Hospital
      • Tenri, Japan, 632-0015
        • Abgeschlossen
        • Tenri Hospital
      • Toon-shi, Japan, 791-0295
        • Abgeschlossen
        • Ehime University Hospital
      • Toyama, Japan, 930-0194
        • Abgeschlossen
        • Toyama University Hospital
      • Ube, Japan, 755-8505
        • Abgeschlossen
        • Yamaguchi University Hospital
      • Ottawa, Kanada, K1N 6N5
        • Rekrutierung
        • The Ottawa Hospital Ottawa NeuroMuscular Centre
      • Floridablanca, Kolumbien, 681004
        • Abgeschlossen
        • Fundación Cardiovascular de Colombia - Instituto del Corazón Floridablanca
      • Medellín, Kolumbien, 50021
        • Aktiv, nicht rekrutierend
        • Instituto Neurológico de Colombia
      • Monterrey, Mexiko, 64710
        • Abgeschlossen
        • i Can Oncology Center
      • Tlalnepantla, Mexiko, 54055
        • Rekrutierung
        • Clinical Research Institute S.C.
      • Chorzów, Polen, 41 500
        • Abgeschlossen
        • Centrum Medyczne
      • Krakow, Polen, 30 539
        • Abgeschlossen
        • Specjalistyczne Gabinety Lekarskie
      • Lublin, Polen, 20 093
        • Abgeschlossen
        • Prywatny Gabinet Lekarski
      • Poznan, Polen, 61 731
        • Aktiv, nicht rekrutierend
        • Clinical Research Center sp z o o MEDIC R s k
      • Almada, Portugal, 2805-267
        • Aktiv, nicht rekrutierend
        • Hospital Garcia de Orta
      • Braga, Portugal, 4710-243
        • Abgeschlossen
        • Hospital de Braga
      • Porto, Portugal, 4200 319
        • Aktiv, nicht rekrutierend
        • Centro Hospitalar de Sao Joao Epe
      • Alicante, Spanien, 03010
        • Aktiv, nicht rekrutierend
        • Hosp. Gral. Univ. de Alicante
      • Barcelona, Spanien, 8035
        • Abgeschlossen
        • Hosp Univ Vall D Hebron
      • Bilbao, Spanien, 48013
        • Aktiv, nicht rekrutierend
        • Hosp. Univ. de Basurto
      • Donostia / San Sebastian, Spanien, 20014
        • Abgeschlossen
        • Hosp. Univ. Donostia
      • Madrid, Spanien, 28040
        • Abgeschlossen
        • Hosp. Clinico San Carlos
      • Seville, Spanien, 41009
        • Aktiv, nicht rekrutierend
        • Hosp. Virgen Macarena
      • Seoul, Südkorea, 05030
        • Abgeschlossen
        • Konkuk University Medical Center
      • Seoul, Südkorea, 02447
        • Abgeschlossen
        • Kyunghee University Medical Center
      • Seoul, Südkorea, 135-710
        • Abgeschlossen
        • Samsung Medical Center
      • Kaohsiung City, Taiwan, 88301
        • Abgeschlossen
        • Kaohsiung Chang Gung Memorial Hospital
      • Taipei, Taiwan, 100
        • Aktiv, nicht rekrutierend
        • National Taiwan University Hospital
      • Taipei, Taiwan, 111
        • Aktiv, nicht rekrutierend
        • Shin Kong Wu Ho Su Memorial Hospital
      • Hradec Králové, Tschechien, 500 05
        • Aktiv, nicht rekrutierend
        • Fakultni nemocnice Hradec Kralove
      • Ostrava, Tschechien, 708 52
        • Abgeschlossen
        • Fakultni Nemocnice Ostrava
      • Pardubice, Tschechien, 53203
        • Abgeschlossen
        • Pardubicka krajska nemocnice a s
    • Colorado
      • Centennial, Colorado, Vereinigte Staaten, 80112
        • Aktiv, nicht rekrutierend
        • IMMUNOe Health and Research Centers
    • Florida
      • Coral Springs, Florida, Vereinigte Staaten, 33067
        • Abgeschlossen
        • Healthcare Innovations Institute Inc
      • Maitland, Florida, Vereinigte Staaten, 32751
        • Abgeschlossen
        • Neurology Associates PA
      • Miami, Florida, Vereinigte Staaten, 33136
        • Aktiv, nicht rekrutierend
        • ALS Center at the University of Miami
    • Georgia
      • Augusta, Georgia, Vereinigte Staaten, 30912
        • Abgeschlossen
        • Augusta University
    • Kansas
      • Kansas City, Kansas, Vereinigte Staaten, 66160
        • Abgeschlossen
        • University of Kansas Medical Center
    • Maryland
      • Baltimore, Maryland, Vereinigte Staaten, 21287
        • Abgeschlossen
        • Johns Hopkins Hospital
    • Massachusetts
      • Boston, Massachusetts, Vereinigte Staaten, 02111
        • Abgeschlossen
        • Boston Clinical Trials
    • Michigan
      • Royal Oak, Michigan, Vereinigte Staaten, 48073
        • Abgeschlossen
        • Beaumont Hospital Royal Oak
    • Missouri
      • Kansas City, Missouri, Vereinigte Staaten, 64128
        • Abgeschlossen
        • Kansas City Veterans Affairs Medical Center
    • New York
      • New York, New York, Vereinigte Staaten, 10032
        • Abgeschlossen
        • The Neurological Institute of New York
      • Patchogue, New York, Vereinigte Staaten, 11772
        • Abgeschlossen
        • South Shore Neurologic Associates - Patchogue
    • North Carolina
      • Charlotte, North Carolina, Vereinigte Staaten, 28204
        • Abgeschlossen
        • The Neurological Institute, PA
    • Ohio
      • Cleveland, Ohio, Vereinigte Staaten, 44195
        • Aktiv, nicht rekrutierend
        • Cleveland Clinic Main Campus
    • Texas
      • Austin, Texas, Vereinigte Staaten, 78756
        • Abgeschlossen
        • Austin Neuromuscular Center
    • Wisconsin
      • Milwaukee, Wisconsin, Vereinigte Staaten, 53215
        • Aktiv, nicht rekrutierend
        • Advocate Health - Aurora St. Luke's Medical Center
      • Birmingham, Vereinigtes Königreich, B15 2TH
        • Abgeschlossen
        • University Hospitals Birmingham NHS Foundation Trust
      • Devon, Vereinigtes Königreich, EX2 5DW
        • Abgeschlossen
        • Royal Devon & Exeter Hospital
      • Glasgow, Vereinigtes Königreich, G514TF
        • Aktiv, nicht rekrutierend
        • NHS Greater Glasgow and Clyde
      • London, Vereinigtes Königreich, NW3 2QG
        • Abgeschlossen
        • Royal Free Hospital
      • Sheffield, Vereinigtes Königreich, S10 2 JF
        • Aktiv, nicht rekrutierend
        • Sheffield Teaching Hospitals NHS Foundation Trust

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Adults greater than or equal to (>=) 18 years of age at the time of consent and as applicable, must also meet the legal age of consent in the jurisdiction in which the study is taking place
  • Diagnosed with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) according to criteria of the European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) 2021, progressing or relapsing forms. CIDP diagnosis to be adjudicated by independent committee during screening period
  • Inflammatory Neuropathy Cause and Treatment (INCAT) disability score between 2 and 9 at the Run-In Baseline visit for participants entering Run-In, or Stage A Baseline visit for participants directly entering Stage A. Participants with an INCAT score of 2 at trial entry must have this score exclusively from the leg disability score
  • Fulfilling any of the following treatment conditions: a) Currently treated with oral corticosteroids (CS) less than or equal to (<=) 20 milligrams (mg)/day; or b) Currently treated with pulsed CS, and/or intravenous immunoglobulin (IVIg) or subcutaneous immunoglobulin (SCIg) and the participant is willing to discontinue no later than the run-in baseline visit; or c) Currently treated with oral CS greater than (>) 20 mg/day and the participant is willing to taper to <=20 mg/day during the run-in period; or d) Without previous treatment (treatment naive); or treatment with CS and/or IVIg or SCIg discontinued at least 3 months prior to screening (untreated)
  • Active disease as determined by CIDP Disease Activity Status (CDAS) score >= 3
  • Other protocol-defined inclusion criteria will apply

Exclusion Criteria:

  • Has a history of severe and/or uncontrolled hepatic (example, viral/alcoholic/autoimmune hepatitis/cirrhosis and/or metabolic liver disease), gastrointestinal, renal, pulmonary, cardiovascular, psychiatric, neurological or musculoskeletal disorder, hypertension and/or any other medical or uncontrolled autoimmune disorder(s) (example, diabetes mellitus) or clinically significant abnormalities in screening laboratory that, might interfere with the participants full participation in the study, or might jeopardize the safety of the participant or the validity of the study results
  • Pure sensory CIDP or chronic immune sensory polyradiculopathy (CISP) (EAN/PNS definition)
  • Any other disease that could better explain the participant's signs and symptoms, such as significant persisting neurological deficits from stroke or central nervous system (CNS) trauma or peripheral neuropathy from another cause such as connective tissue disease or systemic lupus erythematosus
  • Polyneuropathy of other causes, including the following: Multifocal motor neuropathy (MMN); Monoclonal gammopathy of uncertain significance with antimyelin associated glycoprotein (anti-MAG) immunoglobulin M (IgM) antibodies; Hereditary motor neuropathy; Hereditary neuropathy with liability to pressure palsies (HNPP); Polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin change syndromes; Lumbosacral radiculoplexus neuropathy; Polyneuropathy most likely due to diabetes mellitus; Polyneuropathy most likely due to systemic illnesses; Drug- or toxin-induced polyneuropathy Note: A concomitant polyneuropathy of other causes (example, a mild, stable diabetic polyneuropathy) is not necessarily exclusionary if chronic inflammatory demyelinating polyneuropathy (CIDP) is confirmed as the main diagnosis, as determined by the investigator and confirmed by the adjudication committee
  • Has known allergies, hypersensitivity, or intolerance to nipocalimab or its excipients
  • Other protocol-defined exclusion criteria will apply

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Doppelt

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Nipocalimab

Participants in Stage A (Open-label) will receive a loading dose of nipocalimab (Dose 1) intravenous (IV) infusion on Day 1, followed by nipocalimab (Dose 2) IV infusion once every 2 weeks (q2w) from Week 2 to Week 12. Participants who demonstrate evidence of clinical improvement in Stage A (responders) will enter Stage B (Double-blind) and receive nipocalimab (Dose 2) IV infusion q2w starting on Day 1 up to Week 52. After completion of Stage B or discontinuation from Stage B due to relapse, participants will have the option to enter the open label extension (OLE) phase and receive nipocalimab (Dose 2) IV infusion q2w starting on OLE Day 1 until 2 years after marketing authorization in a participant's local country or until nipocalimab becomes available commercially or via other continued access program, whichever comes first.

Nipocalimab will be administered intravenously.

Andere Namen:
  • JNJ-80202135
  • M281
Placebo-Komparator: Placebo

Participants receiving nipocalimab in Stage A and who demonstrate evidence of clinical improvement in Stage A (responders) will enter Stage B (Double-blind) and receive placebo IV infusion q2w starting on Day 1 up to Week 52. After completion of Stage B or discontinuation from Stage B due to relapse, participants will have the option to enter the open label extension (OLE) phase and receive nipocalimab (Dose 2) IV infusion q2w starting on OLE Day 1 until 2 years after marketing authorization in a participant's local country or until nipocalimab becomes available commercially or via other continued access program, whichever comes first.

Placebo will be administered intravenously.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Stage B: Time to First Occurrence of a Relapse Event
Zeitfenster: Up to 52 weeks

Stage B time to first occurrence of a relapse event will be reported.

Up to 52 weeks

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Stage A: Time to Initial Confirmed Evidence of Clinical Improvement (ECI)
Zeitfenster: 12 weeks

Time to initial confirmed ECI will be reported.

12 weeks
Stage A: Percentage of Responders as Determined by ECI
Zeitfenster: 12 weeks

Stage A percentage of responders as determined by ECI will be reported.

12 weeks
Stage A: Change from Baseline Over Time in Adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Scale Score
Zeitfenster: Baseline to 12 weeks

Change from Stage A baseline over time in adjusted INCAT disability scale score will be reported. The INCAT disability scale is a clinician-rated assessment that measures activity limitation and degree of functional disability. The INCAT scale is an ordinal scale scored from 0 to 10, with higher scores indicating more disability.

Baseline to 12 weeks
Stage A: Change from Stage A Baseline Over Time in Medical Research Council (MRC) Muscle Grading Scale Sum Score
Zeitfenster: Baseline to 12 weeks

Change from Stage A baseline over time in MRC muscle grading scale sum score will be reported. The MRC muscle grading scale is a clinician-rated outcome that provides a strength rating (on a scale from 0 [no visible contraction] to 5 [normal]) in 6 muscles collected bilaterally: deltoid, biceps, wrist extensors, iliopsoas, quadriceps, tibialis anterior. Lower scores indicate greater impairment.

Baseline to 12 weeks
Stage A: Change from Baseline Over Time in Inflammatory Rasch-Built Overall Disability Scale (I-RODS) Centile Score
Zeitfenster: Baseline to 12 weeks

Change from Stage A baseline over time in I-RODS centile score will be reported. The I-RODS comprises of 24 items representing common daily activities that address upper and lower limb disability and range in difficulty from very easy to very difficult. Lower scores indicate greater activity and social participation limitations.

Baseline to 12 weeks
Stage A: Change from Baseline Over Time in Mean Grip Strength (Dominant Hand)
Zeitfenster: Baseline to 12 weeks

Change from Stage A baseline over time in mean grip strength (dominant hand) will be reported. Grip Strength is a quantifiable, objective performance outcome measure of hand strength, which can be measured using various devices (for example, Martin Vigorimeter and Jamar Dynamometer).

Baseline to 12 weeks
Stage A: Change from Baseline Over Time in Mean Grip Strength (Non-Dominant Hand)
Zeitfenster: Baseline to 12 weeks

Change from Stage A baseline over time in mean grip strength (non-dominant hand) will be reported. Grip Strength is a quantifiable, objective performance outcome measure of hand strength, which can be measured using various devices (for example, Martin Vigorimeter and Jamar Dynamometer).

Baseline to 12 weeks
Stage B: Time to First Adjusted INCAT Disability Scale Score Deterioration Relative to Baseline
Zeitfenster: Up to 52 weeks

Time to first adjusted INCAT disability scale score deterioration relative to Stage B baseline will be reported.

Up to 52 weeks
Stage B: Time to First Switch to Intravenous Immunoglobulin (IVIg) or Other Standard of Care (SoC) as a Result of Investigator-assessed Lack of Efficacy as Confirmed by an Independent RAC Relative to Baseline
Zeitfenster: Up to 52 weeks

Time to first switch to IVIg or other SoC as a result of investigator-assessed lack of efficacy as confirmed by an independent Relapse Adjudication Committee (RAC) relative to Stage B baseline will be reported.

Up to 52 weeks
Stage B: Change from Baseline Over Time in Adjusted INCAT Disability Score
Zeitfenster: Up to 52 weeks

Change from Stage B baseline over time in adjusted INCAT disability score will be reported.

Up to 52 weeks
Stage B: Change from Baseline Over Time in MRC Muscle Grading Scale Sum Score
Zeitfenster: Up to 52 weeks

Change from Stage B baseline over time in MRC Muscle Grading Scale Sum score will be reported.

Up to 52 weeks
Stage B: Change from Baseline Over Time in I-RODS Centile Score
Zeitfenster: Up to 52 weeks

Change from Stage B baseline over time in I-RODS centile score will be reported.

Up to 52 weeks
Stage B: Change from Baseline Over Time in Mean Grip Strength (Dominant Hand)
Zeitfenster: Up to 52 weeks

Change from Stage B baseline over time in mean grip strength (dominant hand) will be reported. Grip Strength is a quantifiable, objective performance outcome measure of hand strength, which can be measured using various devices (for example, Martin Vigorimeter and Jamar Dynamometer).

Up to 52 weeks
Stage B: Change from Baseline Over Time in Mean Grip Strength (Non-Dominant Hand)
Zeitfenster: Up to 52 weeks

Change from Stage B baseline over time in mean grip strength (non-dominant hand) will be reported. Grip Strength is a quantifiable, objective performance outcome measure of hand strength, which can be measured using various devices (for example, Martin Vigorimeter and Jamar Dynamometer).

Up to 52 weeks
Stage B: Number of Participants with Binary Response Endpoint Satisfying all 4 Conditions: a) An Improved Adjusted INCAT Disability Score Compared to Baseline; b) Not Relapsing; c) Not Switching to SoC; d) Not Discontinuing Treatment
Zeitfenster: Up to 52 weeks

Number of participants with Binary response endpoint satisfying all 4 conditions: a) an improved adjusted INCAT Disability Score compared to Stage B baseline; b) not relapsing; c) not switching to SoC; d) not discontinuing treatment, will be reported.

Up to 52 weeks
Percentage of Participants with Treatment-emergent Adverse Events (TEAEs)
Zeitfenster: Stage A: 12 weeks; Stage B: Up to 52 weeks

An adverse event (AE) is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAEs are defined as AEs with onset or worsening on or after date of first dose of study treatment

Stage A: 12 weeks; Stage B: Up to 52 weeks
Percentage of Participants with Serious Adverse Events (SAEs)
Zeitfenster: Stage A: 12 weeks; Stage B: Up to 52 weeks

SAE is an adverse event resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect; suspected transmission of any infectious agent via a medicinal product or medically important.

Stage A: 12 weeks; Stage B: Up to 52 weeks
Number of Participants with Change in Electrocardiogram (ECG) Values Over Time
Zeitfenster: Stage A: 12 weeks; Stage B: Up to 52 weeks

Number of participants with change in ECG values over time will be reported.

Stage A: 12 weeks; Stage B: Up to 52 weeks
Number of Participants with Change in Vital Signs Values Over Time
Zeitfenster: Stage A: 12 weeks; Stage B: Up to 52 weeks

Number of participants with change in vital signs values over time will be reported.

Stage A: 12 weeks; Stage B: Up to 52 weeks
Number of Participants with Change in Clinical Laboratory Values Over Time
Zeitfenster: Stage A: 12 weeks; Stage B: Up to 52 weeks

Number of participants with change in clinical laboratory values over time will be reported.

Stage A: 12 weeks; Stage B: Up to 52 weeks
Number of Participants with Clinically Significant ECG Abnormalities
Zeitfenster: Stage A: 12 weeks; Stage B: Up to 52 weeks

Number of participants with clinically significant ECG abnormalities will be reported.

Stage A: 12 weeks; Stage B: Up to 52 weeks
Number of Participants with Clinically Significant Vital Signs Abnormalities
Zeitfenster: Stage A: 12 weeks; Stage B: Up to 52 weeks

Number of participants with clinically significant vital signs abnormalities will be reported.

Stage A: 12 weeks; Stage B: Up to 52 weeks
Number of Participants with Clinically Significant Clinical Laboratory Abnormalities
Zeitfenster: Stage A: 12 weeks; Stage B: Up to 52 weeks

Number of participants with clinically significant clinical laboratory abnormalities will be reported.

Stage A: 12 weeks; Stage B: Up to 52 weeks
Percentage of Participants with Suicidal Ideation or Suicidal Behavior based on the Columbia-Suicide Severity Rating Scale (C-SSRS)
Zeitfenster: Stage A: 12 weeks; Stage B: Up to 52 weeks

Percentage of participants with suicidal ideation or suicidal behavior based on the C-SSRS will be reported.

Stage A: 12 weeks; Stage B: Up to 52 weeks
Serum Nipocalimab Concentrations Over Time in Participants Receiving Active Study Intervention
Zeitfenster: Stage A: 12 weeks; Stage B: Up to 52 weeks

Serum nipocalimab concentrations over time in participants receiving active study intervention will be reported.

Stage A: 12 weeks; Stage B: Up to 52 weeks
Number of Participants with Anti-drug Antibodies (ADA) to Nipocalimab
Zeitfenster: Stage A: 12 weeks; Stage B: Up to 52 weeks

Number of participants with ADA to Nipocalimab will be reported.

Stage A: 12 weeks; Stage B: Up to 52 weeks
Titers of ADA to Nipocalimab
Zeitfenster: Stage A: 12 weeks; Stage B: Up to 52 weeks

Titers of ADA to nipocalimab will be reported.

Stage A: 12 weeks; Stage B: Up to 52 weeks
Number of Participants with Neutralizing Antibodies (NAb) to Nipocalimab
Zeitfenster: Stage A: 12 weeks; Stage B: Up to 52 weeks

Number of participants with NAb to Nipocalimab will be reported.

Stage A: 12 weeks; Stage B: Up to 52 weeks
Change from Baseline in Total Serum Immunoglobulin (IgG) Concentrations Levels Over Time
Zeitfenster: Stage A: Baseline to 12 weeks; Stage B: Baseline up to 52 weeks

Change from baseline in total serum IgG concentrations levels over time will be reported.

Stage A: Baseline to 12 weeks; Stage B: Baseline up to 52 weeks

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Ermittler

  • Studienleiter: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

23. September 2022

Primärer Abschluss (Geschätzt)

15. Dezember 2026

Studienabschluss (Geschätzt)

11. Juli 2028

Studienanmeldedaten

Zuerst eingereicht

7. April 2022

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

7. April 2022

Zuerst gepostet (Tatsächlich)

14. April 2022

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

3. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

2. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • CR109195
  • 80202135CDP3001 (Andere Kennung: Janssen Research & Development, LLC)
  • 2021-003234-37 (EudraCT-Nummer)
  • 2023-508425-28-00 (Registrierungskennung: EUCT number)
  • 2023 (US NIH Stipendium/Vertrag)

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .